Celltrion Inc.
Scope
Date
~
-
Bio & Pharma
Celltrion Healthcare to supply Yuflyma to US pharmacy chain
South Korea's Celltrion Healthcare Co. has inked a deal with the US specialty pharmacy chain CarePartners Pharmacy to supply its autoimmune disease ...
Oct 16, 2023 (Gmt+09:00)
-
Bio & Pharma
Proxy adviser ISS backs drug giant Celltrion's merger plan
South Korean drug giant Celltrion Group has received a positive recommendation from Institutional Shareholder Services (ISS), a global leading proxy...
Oct 06, 2023 (Gmt+09:00)
-
Bio & Pharma
Celltrion Pharm gets GMP certification from Japan
Celltrion Pharm Inc. announced on Wednesday that its pre-filled syringe (PFS) production facility in Cheongju, North Chungcheong Province has obtain...
Sep 27, 2023 (Gmt+09:00)
-
Bio & Pharma
Celltrion gets sales approval for Yuflyma in Japan
South Korea's biopharmaceutical company Celltrion Inc. announced on Tuesday that it has secured approval from the Japanese Ministry of Health, Labou...
Sep 26, 2023 (Gmt+09:00)
-
Bio & Pharma
Celltrion signs largest-ever quarterly deal with global sales affiliate
Celltrion Inc., a South Korean biopharmaceutical giant, said Monday it will provide biosimilars worth 423.6 billion won ($323.6 million), its larges...
Sep 25, 2023 (Gmt+09:00)
-
Bio & Pharma
Celltrion Healthcare to supply Yuflyma to five regional gov’ts in Italy
South Korea's Celltrion Healthcare Co. announced on Monday that it will supply its biosimilar Yuflyma (active ingredient: adalimumab) for the treatm...
Sep 18, 2023 (Gmt+09:00)
-
KOREA Investment Week 2023
Celltrion builds clinical data bank for new biosimilars
The use of data and computing is a new paradigm in the biopharmaceutical industry, reducing the new drug development time and cost, Celltrion Inc. C...
Sep 12, 2023 (Gmt+09:00)
-
Corporate strategy
Korea Inc. to focus more on India, Vietnam as biz partners
South Korean companies are set to concentrate more on business with emerging markets including India and Vietnam than Asian major countries such as ...
Sep 08, 2023 (Gmt+09:00)
-
Bio & Pharma
Celltrion to expand new plant for drug products
South Korean biopharmaceutical firm Celltrion Inc. announced on Tuesday that it plans to enlarge its finished pharmaceuticals manufacturing facility...
Sep 05, 2023 (Gmt+09:00)
-
Bio & Pharma
Celltrion to release Stelara biosimilar in US from March 2025
South Korean biopharmaceutical company Celltrion Inc. announced on Friday that it has completed a patent agreement with Johnson & Johnson, the m...
Aug 25, 2023 (Gmt+09:00)
-
Bio & Pharma
Celltrion considers listing holding firm after merger of 3 units
South Korean drug giant Celltrion Group will consider listing its holding company if necessary, after it completes the merger of three affiliates &n...
Aug 24, 2023 (Gmt+09:00)
-
Bio & Pharma
Celltrion’s Vegzelma listed on prescription of 10 private US insurers
South Korea’s Celltrion Healthcare Co. announced on Wednesday that it has signed contracts with 10 insurance providers in the US to boost the ...
Aug 23, 2023 (Gmt+09:00)
-
Bio & Pharma
Celltrion gets OK partial approval for phase 3 of biosimilar in Europe
South Korean biopharmaceutical company Celltrion Inc. announced on Tuesday that it has received approval from the European Medicines Agency (EMA) fo...
Aug 22, 2023 (Gmt+09:00)
-
Bio & Pharma
Celltrion to merge with global sales affiliate by end-2023
South Korean pharmaceutical giant Celltrion Group has begun procedures to merge biopharmaceuticals developer and producer Celltrion Inc. with global...
Aug 17, 2023 (Gmt+09:00)
-
Pre-IPOs
SK Pharmteco to raise $500 mn in pre-IPO, aims for 2025 listing
SK Pharmteco Co., South Korean conglomerate SK Group’s contract development and manufacturing organization (CDMO), is set to raise $500 millio...
Jul 18, 2023 (Gmt+09:00)
-
Carbon neutrality
Samsung Biologics, Celltrion pledge major CO2 cuts
South Korea’s No. 1 biopharmaceutical company Samsung BioLogics Co. and No. 2 Celltrion Inc. produced higher CO2 emissions last year than in 2...
Jul 10, 2023 (Gmt+09:00)
-
Bio & Pharma
Celltrion Healthcare launches Humira biosimilar Yuflyma in US
South Korean biopharmaceutical company Celltrion Healthcare on Monday said it launched the day before on the US market Yuflyma, a biosimilar of the ...
Jul 04, 2023 (Gmt+09:00)
-
Bio & Pharma
Celltrion applies for approval in US for eye treatment biosimilar
South Korean biopharmaceutical company Celltrion Inc. on Friday said it applied for approval from the US Food and Drug Administration (FDA) for CT-P...
Jun 30, 2023 (Gmt+09:00)
-
Bio & Pharma
Celltrion puts Takeda’s assets up for sale after 3 years
South Korea’s Celltrion Inc. has put its Japanese Takeda Pharmaceutical Co.'s primary care assets acquired in 2020 on sale as the biosimilar g...
Jun 18, 2023 (Gmt+09:00)
-
Bio & Pharma
Celltrion wins phase 3 IND approval for Ocrevus biosimilar in US
South Korea's biopharmaceutical company Celltrion Inc. announced that it received on Thursday approval from the US Food and Drug Administration (FDA...
Jun 15, 2023 (Gmt+09:00)
-
Bio & Pharma
Celltrion to expand biosimilar portfolio to 11 by 2025
South Korea's biopharmaceutical company Celltrion Inc. announced on Tuesday that it plans to beef up its portfolio by applying for regulatory approv...
Jun 13, 2023 (Gmt+09:00)
-
Bio & Pharma
Celltrion to develop Humira biosimilar oral medication with US firm
South Korea's biopharmaceutical company Celltrion Inc. announced on Monday that it has signed a contract with the US biotech firm Rani Therapeutics ...
Jun 05, 2023 (Gmt+09:00)
-
Bio & Pharma
Celltrion’s Remsima SC praised in Europe as preferred biosimilar
MILAN – South Korea's biopharmaceutical company Celltrion Inc. is known in Europe for its biosimilar products such as autoimmune disease treat...
Jun 02, 2023 (Gmt+09:00)
-
Bio & Pharma
Celltrion unveils phase 1 clinical data of Actemra biosimilar in Europe
South Korean biosimilar giant Celltrion Inc. revealed on Wednesday the highly anticipated clinical phase 1 data for its Actemra biosimilar, CT-P47, ...
May 31, 2023 (Gmt+09:00)
-
Bio & Pharma
BIO USA 2023 to draw S.Korean biotech leaders, startups
More than 500 South Korean companies from top business groups to AI-based biotech startups are slated to attend the Bio International Convention 202...
May 30, 2023 (Gmt+09:00)
-
Bio & Pharma
Celltrion gets FDA approval for Humira biosimilar CT-P17
South Korean biopharmaceutical company Celltrion Inc. announced on Wednesday that it has obtained product approval from the US Food and Drug Adminis...
May 24, 2023 (Gmt+09:00)
-
Bio & Pharma
Celltrion Healthcare launches Remsima SC in Brazil
South Korean biopharmaceutical company Celltrion Healthcare Co. revealed on Monday its introduction of Remsima SC, a treatment for autoimmune diseas...
May 22, 2023 (Gmt+09:00)
-
Mergers & Acquisitions
Celltrion drops bid to acquire Baxter’s biopharm unit
Celltrion Inc. announced on Tuesday it has decided not to pursue the acquisition of the biopharmaceutical unit of U.S. medical device maker Baxter I...
May 09, 2023 (Gmt+09:00)
-
Bio & Pharma
Celltrion applies for Phase 3 clinical trials in Europe for biosimilar
South Korea’s Celltrion Inc. is speeding up global clinical trials of its biosimilar of the multiple sclerosis (MS) treatment Ocrevus (active ...
May 03, 2023 (Gmt+09:00)
-
Energy
SK, KHNP partner with TerraPower for SMR development
SK Inc., SK Innovation Co. are partnering with Korea Hydro & Nuclear Power Co. (KHNP) and TerraPower, a US small modular reactor (SMR) des...
Apr 26, 2023 (Gmt+09:00)